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Abstract
Objectives—To test the hypothesis that changes in DNA methylation are involved in vitamin D
deficiency–related immune cell regulation using an unbiased genome-wide approach combined
with a genomic and epigenomic integrative approach.
Study design—We performed a genome-wide methylation scan using the Illumina
HumanMethylation 27 BeadChip on leukocytes DNAs of 11 cases of vitamin D deficiency (serum
25(OH)D≤ 25 nmol/L) and 11 age-matched controls (serum 25(OH)D>75 nmol/L); the subjects
were African American normal-weight (BMI<85th percentile) males aged 14-19 years. The
Limma package was used to analyze each CpG site for differential methylation between cases and
controls. To correct for multiple testing, the set of raw p values were converted to false discovery
rates (FDR). We also compared our findings with the recent data from GWAS of circulating
25(OH) D levels and then performed a permutation test to examine whether the “double hit” genes
were randomly enriched.
Results—A total of 79 CpG sites achieved raw p<0.001. Of the 79 CpG sites, 2 CpG sites
survived multiple testing: cg16317961 (raw p=3.5 × 10-6, FDR=0.078, in MAPRE2) and
cg04623955 (raw p=5.9 × 10-6, FDR=0.078, in DIO3). Furthermore, 3 out of the 4 genes
previously identified in the two GWAS studies were also significant at the methylation level
(DHCR7: cg07487535, p=0.015 & cg10763288, p=0.017; CYP2R1: cg25454890, p=0.040;
CYP24A1: cg18956481, p=0.022), reflecting significant enrichment (p=0.0098).
Conclusion—Severe vitamin D deficiency is associated with methylation changes in leukocyte
DNA. The genomic and epigenomic approach reinforce the crucial roles played by the DHCR7,
CYP2R1 and CYP24A1 genes in vitamin D metabolism.
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Vitamin D is considered to play an important role in a broad range of bodily functions
beyond bone health 1-4. The latest assay-adjusted National Health and Nutrition
Examination Survey (NHANES) 2001-2006 in 5,867 adolescents aged 12-19 years
demonstrates that low 25-hydroxyvitamin D [25(OH)D] is associated with several
cardiometabolic risk factors such as metabolic syndrome and insulin resistance5.
The prevalence of 25(OH)D levels of < 25 nmol/L increased from 2% during NHANES
1988-1994 to 6% during NHANES 2001-2004. The prevalence of 25(OH)D levels of < 25
nmol/L in African Americans rose from 9% to 29%6. We recently reported that African
American adolescents living in a year-round sunny climate area like Augusta, Georgia
(∼33° North latitude), circulating 25(OH)D concentrations were less than half those of
Caucasian adolescents in every season7. In addition, 6.2% African American males and
17.2% African America females suffered from severe vitamin D deficiency (<25 nmol/L)7.
Vitamin D has known immunomodulatory effects on a wide range of immune cells
including activated CD4 and CD8 T lymphocytes, B lymphocytes, macrophages as well as
dendritic cells1,8. Serum 25(OH)D levels are inversely associated with levels of C-reactive
protein (CRP), interleukin-6 (IL-6) and tumor necrosis factor -α (TNF-α)9. Vitamin D
supplementation has been shown to down-regulate nuclear factor-kB activity, increase anti-
inflammatory IL-10 levels and decrease the pro-inflammatory cytokines IL-6, IL-12,
interferon-γ and TNF-α10-11. Recent hierarchical and model-based clustering analysis of 200
vitamin-related proteins revealed that vitamin D-related proteins were strongly represented
among network hubs, highlighting the pervasive effects of this nutrient primarily related to
immune system and cancer process12.
Epigenetic factors are at the interface between environmental stimuli and long-lasting
molecular, cellular and behavioral phenotypes13. Epigenetics defines all meiotically and
mitotically heritable changes in chromosome function/gene expression that are not coded in
the DNA sequence itself. Recently, there has been a greater appreciation of the role of
histone modification in vitamin D-mediated immune-regulatory and inflammation
response14. However, whether DNA methylation is also involved in vitamin D-mediated
immune regulation remains unknown.
Genome-wide association studies (GWAS) of circulating 25 (OH)D, identified 4 genes,
which are involved in cholesterol synthesis, hydroxylation, and vitamin D transport15-16.
Genetic variation at these loci identifies individuals who have substantially elevated risk of
vitamin D insufficiency. Therefore, the goal of this study was to characterize DNA
methylation profile in peripheral blood leukocytes in African American adolescents with and
without severe vitamin D deficiency using an unbiased genome-wide approach combined
with a genomic and epigenomic integrative approach comparing our methylation profiling
data with the candidate genes identified from GWAS on circulating vitamin D and vitamin
D insufficiency
Methods
The genome-wide methylation analysis was conducted in 11 children with vitamin D
deficiency (plasma 25(OH)D≤ 25 nmol/L) and 11 age-matched controls (plasma 25(OH)D>
75 nmol/L) selected at the two extreme ends of the 25(OH)D distribution (extreme
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phenotypes) from previous studies7,17. All the subjects from the two studies were apparently
healthy and were not taking any medications or vitamin supplements. The 22 subjects aged
14-19 were selected based on the following criteria: (1) African American ancestry by self-
report; (2) male; (3) apparently healthy (normotensive, non-diabetic) (4) body mass index
(BMI) < 85th percentile for age and sex; (5) having leukocyte DNA available; (6) at the
lowest and the highest ends of the 25(OH)D distribution. The institutional Review Board at
the Georgia Health Sciences University approved the studies. Informed consent was
obtained from all subjects and by parents if subjects were less than 18 years of age.
Height and weight were measured by standard methods using a wall-mounted stadiometer
and a scale, respectively. BMI was calculated as weight/height2. After participants quietly
rested for 10 minutes, systolic blood pressure and diastolic blood pressure were measured in
a supine position with a Dinamap monitor (Critikon, Tampa, FL). Blood samples were
collected. The plasma and buffy coat were separated and stored at -80°C.
Plasma 25(OH)D measurement
Liquid chromatography tandem mass spectroscopy (LC-MS/MS) was used to measure
circulating plasma levels of 25(OH)D2 and 25(OH)D3 as described previously18. LC-MS/
MS procedures is one of the most sensitive methods of measuring 25 (OH)D19. The
detection limits for 25(OH)D2 and 25(OH)D3 were 4.6 and 1.2 nmol/L. The detection range
is 1-250 nmol/L18. The intra-assay (inter-assay) coefficients of variation for 25(OH)D2 and
25(OH)D3 were 6-9% (9-12%) and 7-11% (8-13%) respectively. Regarding the assay
specificity, LC–MS/MS has the advantage of being able to measure both 25(OH)D2 and
25(OH)D3 independently19. The levels of total 25(OH)D including 25(OH)D2 and
25(OH)D3 were used in the selection process.
Genome-wide methylation chip
The HumanMethylation27 BeadChip from Illumina (Illumina, San Diego, CA, USA) was
used. This chip can quantitatively measure 27, 000 CpG sites, covering more than 14,000
well-annotated genes at single-CpG resolution. After bisulfite treatment, 200ng of the
converted DNA was whole genome amplified (WGA) and enzymatically fragmented. The
bisulfite-converted WGA-DNA samples were purified and applied to the BeadChips. Image
processing and intensity data extraction were performed according to Illumina's instructions
(http://www.illumina.com/products/infinium_humanmethylation27_beadchip_kits.ilmn).
Each methylation data point is represented by fluorescent signals from the methylated and
unmethylated alleles. DNA methylation beta values are continuous variables between 0
(completely unmethylated) and 1 (completely methylated), representing the ratio of the
intensity of the methylated bead type to the combined locus intensity. Initial array
processing and quality control were performed with BeadStudio software.
Statistical Analyses
The general characteristics of the subjects are presented as mean ± SD. Independent t-tests
were conducted to examine the differences of covariates between cases and controls using
SPSS17.0 (SPSS Inc., Chicago, IL). For the genome-wide methylation analysis, the Limma
package20 was used to analyze each CpG site for differential methylation between cases and
controls under the design matrix of a paired test. CpG sites on the X and Y chromosomes
were excluded from the analysis. Each CpG site was assigned a raw p value based on a
moderated t statistic. To correct for multiple testing, the set of raw p values were converted
to false discovery rates (FDR) according to Benjamini and Hochberg21. Rather than
expressing the probability of a single false-positive result among all tests, the FDR value
estimates the proportion of results declared interesting that are actually false. We used a
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FDR value threshold of 0.2022, meaning that one should expect at most 20% of declared
discovery to be false.
Gene Ontology (GO) analysis was conducted with the FatiGO tool 23. FatiGO takes two lists
of genes and converts them into two lists of GO terms. Then a Fisher's exact test for 2 × 2
contingency tables was used to check for significant over-presentation of GO terms in one of
the sets with respect to the other one. Multiple testing correction (indexed by adjusted p-
values) to account for the multiple hypotheses tested (one for each GO term) was applied to
reduce false positives. Because at least two CpG sites were included for the majority of
genes in this genome wide chip, for each gene we only selected the CpG sites with the
lowest p value.
Additionally, we applied an integrative approach compared our methylation profiling data
with the candidate SNPs identified from GWAS on circulating vitamin D and vitamin D
insufficiency15-16 to identiy the “double hit” genes. We then performed a permutation test to
examine whether the “double hit” genes were randomly enriched (STATA 8, StataCorp,
College station, TX).
Results
Table I displays the general characteristics of the study sample. Except for the plasma
25(OH)D concentrations, all other variables were similar for the case and control groups.
The Figure is a volcano plot showing the raw p-values for all CpG sites versus mean
methylation difference between the severe vitamin D deficiency group and the control
group. In general, participants with severe vitamin D deficiency showed a pattern of reduced
methylation compared with controls. Table II lists the top 10 most differently methylated
CpG sites. Again, 9 out of the top 10 CpG sites showed reduced methylation levels
compared with controls. The top two significan CpG sites survived multiple testing using an
FDR of 10% (cg16317961, raw p = 3.5 × 10-6, FDR=0.078, in MAPRE2; cg04623955, raw
p= 5.92 × 10-6, FDR=0.07, in DIO3).
Gene Ontology analysis was performed to test whether some common functional trends in
molecular functions and biological processes were associated with the genes exhibiting
differences between cases of vitamin D deficiency and controls in the genome-wide chip.
We assigned those genes with a raw p <0.001 to the first list (n=79) and included all other
genes in the second list (n=13,811). As expected from a study in only 22 subjects, we did
not observe any GO categories that survived multiple testing. Overall, we observed enriched
functional processes that are potentially relevant for regulation of: metabolic processes;
cellular development; cell adhesion, motility and differentiation; cellular defense;
transcriptional factor binding; sterol binding; and Wnt-protein binding. Table III (available
at www.jpeds.com) lists the GO categories with raw p values < 0.05.
Furthermore, our genomic and epigenomic integration approach showed that of the 3 loci
(within or near GC, DHCR7/NADSYN1 and CYP2R1 genes) independently discovered in
these two recent GWAS studies15-16, the methylation differences in the promoter CpG sites
of the two genes (DHCR7 and CYP2R1) were statistically significant between the severe
vitamin D deficiency group and the control group (DHCR7: cg07487535, p=0.015 &
cg10763288, p=0.017; CYP2R1: cg25454890, p=0.040). Moreover, a SNP near CYP24A1
showed an overall p value of 6.0 × 10-10 in one of the GWAS studies16. The methylation
differences in the CpG site of the CYP24A1 gene were also statistically significant between
the severe vitamin D deficiency group and the control group (cg18956481, p=0.022, Table
IV).
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To test whether the above finding (ie, 3 of the 4 candidates with GWA genes were
significantly associated with severe vitamin D deficiency) was randomly enriched, we
performed the permutation test. Of total 26,486 CpG sites, 26,460 were mapped on 13,872
genes. For each gene, we assigned the highest statistic value (i.e. smallest p value) among
the multiple CpG sites mapped to the gene as the statistic value of the gene. Four genes were
randomly selected from these 13,872 genes. The number of genes with p value ≤0.05 was
counted. This procedure was repeated 10000 times, and a distribution of count number of
significant genes (p≤0.05) out of 4 genes was obtained. In these 10000 repetitions, only 98
had a count number equal or larger than 3. In other words, these 3 genes (DHCR7, CYP2R1
and CYP24A1) were significantly enriched with respect to severe vitamin D deficiency
(p=0.0098), indicative of not a chance finding.
Discussion
In this study, we identified methylation differences in leukocyte DNA in relation to vitamin
D deficiency. Moreover, the genomic and epigenomic integrative approach confirmed the
DHCR7, CYP2R1 and CYP24A1 genes, which may play crucial roles in vitamin D
metabolism.
MAPRE2 (also known as EB2, RP1) has the most significant differently methylated
promoter CpG site. The methylation level was 37% lower (3.7%/10%) in the group with
vitamin D deficiency compared with the controls. Moreover, the other CpG site of the
MAPRE2 gene was also significantly differentially methylated (p=0.016). The MAPRE gene
family consists of three members (MAPRE1, 2 and 3) that code for three microtubule
associated proteins. They are important for many cellular processes i.e. cell division,
cytoplasmatic organization, maintenance of cell polarity, chromosome segregation and cell
migration24-26. These microtubule associated proteins regulate microtubule functions and
dynamics, which is fundamentally important to the way cells response to their
environment24, 27. MAPRE2 is expressed in T cells and lymphocyte tumor cell lines and
activated by cell surface antigens and/or cytokines28. MAPRE2 over expression induced
nuclear accumulation of β-catenin and promoted the transcriptional activity of β-catenin/T-
cell factor29. Because the expression is rapidly up-regulated in activated T cells, MAPRE2 is
considered a member of the immediate-early T-cell regulatory gene family28. The proteins
encoded by the immediate-early gene can act as pleiotropic regulators of cellular activation,
such as transcription factors and proteins involved in signal transduction cascades30.
MAPRE2 can also be found in rapidly proliferating tumor cells and its expression correlates
with the cell cycle activity indicates that its protein (RP1) might be critically involved in
processes controlling cell proliferation28, 31.
DIO3, the second most significant site identified, is located in the imprinted region in
chromosome 14q32 and plays a critical role in maturation and function of the thyroid axis
which is also critical to the development of the human central nervous system32. Meta-
analysis of genes modulating intracellular T3 bio-availability has revealed a possible role for
DIO3 gene in osteoarthritis33. Recent data have shown that this gene is hypermethylated in
hematological tumors34-35. In the present study, the promoter CpG site methylation was
24.2% (4.6%/19%) higher in the group with vitamin D deficiency as compared with the
controls.
As demonstrated by previous studies, 3-10% of the human genome is regulated directly and
indirectly by the vitamin D endocrine system36-37. Genome-wide VDR has a few thousand
chromosomal target sites that regulate several hundred 1, 25(OH)2D3 target genes in a cell-
specific fashion38-39. Methylation/demethylation reflects vitamin D-mediated transcriptional
control via vitamin D response element (VDRE)40. VDRE can directly bind to DNA
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methyltransferases 1 and 3B (DNMT1 and DNMT3B)41. A global transcriptomic study
showed that 1, 25 (OH)2D3 significantly changed the RNA expression profile in human
colon cancer cells involving many different cell functions, including transcription, cell
adhesion, DNA synthesis, apoptosis and intracellular signaling42. Recent hierarchical and
model-based clustering analysis of the protein-protein interaction network of 200 vitamin-
related proteins revealed that a subgroup of 22 proteins that are highly central, most of these
proteins are key immune regulators such as cytokines and transcription factors such as
SMAD3 and VDR. Moreover, 17 out of the 22 central proteins in the protein-protein
interaction network are vitamin D-related proteins, highlighting the pervasive effects of this
nutrient primarily related to immune system and cancer process12. We also showed that
many functional pathways are involved in severe vitamin D deficiency-related methylation
changes in leukocytes including regulation of metabolic processes, cellular development,
cell adhesion, motility and differentiation, cellular defense response as well as
transcriptional factor binding, sterol binding, and Wnt-protein binding (Table III). The
finding that vitamin D receptor deficiency enhances Wnt/β-Catenin signaling in human color
cancer cells43 parallels our finding that Wnt-protein binding was an enriched molecular
function for differentially methylated genes in leukocytes of individuals with vitamin D
deficiency.
Our epigenomic findings confirmed 3 genes out of the 4 genes in GWAS findings, which
reinforce the crucial roles played by those 3 genes in vitamin D metabolism. DHCR7
encodes the enzyme 7-dehydrocholesterol (7-DHC) reductase, which converts 7-DHC to
cholesterol, thereby removing the substrate from the synthetic pathway of vitamin D3, a
precursor of 25OHD3. DHCR7 is a novel gene for association with vitamin D levels
identified in the two recent GWAS studies15-16. CYP2R1 (cytochrome P450, family 2,
subfamily R, polypeptide 1) encodes a hepatic microsomal enzyme 25-hydroxylase that
converts vitamin D3 to an active vitamin D receptor ligand. Previous candidate44-45 and
GWAS15-16 studies suggested that this gene is associated with vitamin D metabolism.
CYP24A1, which encodes 24-hydroxylase, has been identified as a candidate gene for
vitamin D insufficiency in one GWAS16, not the other15. This mitochondrial protein
initiates the degradation of 1,25-dihydroxyvitamin D3 and plays a role in calcium
homeostasis and vitamin D metabolism. Our findings suggested that subjects with vitamin D
deficiency are more likely to have reduced synthesis and increased metabolism of active
vitamin D. Our epigenetic data provide the additional body of evidence that those 3 enzymes
are the key enzymes underlying the crucial steps in vitamin D metabolism.
The observed DNA methylation differences between cases with vitamin D deficiency and
controls were relatively small (<5%), which is in agreement with the two recent genome-
wide methylation studies in leukocyte DNA on obesity and type 2 diabetes46,47. Toperoff et
al demonstrated that the odd of belonging to the type 2 diabetes group increased by 6% for
every 1% decrease in methylation in whole blood DNA47. It is possible that the methylation
differences identified in leukocyte DNA could be attributed to differences in the leukocyte
profile, rather than epigenetic changes induced within specific subtypes of leukocytes.
However, Toperoff et al further analyzed the potential contribution of differential case-
control composition of blood cells to the observed methylation differences. No significant
differences in blood counts appeared between cases and controls, and adjustment for blood
lineage count did not affect the association of methylation with the incidence of type 2
diabetes47.
Our use of a hypothesis-free approach avoided the limitations imposed by candidate gene
studies and allowed us to search the whole genome in an unbiased manner. Genomic and
epigenomic data integration provides greater understanding of physiology and etiology of
the complex traits. The use of extreme phenotypes based on plasma vitamin D values
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maximized the power to make discoveries. The selection of normal weight cases and
controls eliminated the confounding effect of obesity on methylation differences. The focus
on adolescents prior to the development of target organ damages optimized the chances to
unmask important etiologic relationships.
Several limitations are noteworthy. First, we were unable to determine whether the between
group methylation differences we observed were associated with differences in transcription
level between the two groups because cellular RNA samples were unavailable. Second,
although we hypothesize that severe vitamin D deficiency will lead to methylation changes
in leukocyte DNA, our case-control study design cannot determine whether the identified
methylation differences are the cause or the consequence of severe vitamin D deficiency.
Third, the methylation profiling was done in whole blood leukocytes. However, the blood
lineage data was not collected at the time of sampling. Forth, the Infinium
HumanMethylation27 Beadchip was used because of the availability at that time. The
limited coverage of this genome-wide chip will restrict the findings to certain CpG sites
within certain genes. Genome chips with more complete coverage such as the recently
released 450K Infinium Methylation BeadChip from Illumina should be used in future
studies. Last, the study is limited by lack of cases with severe vitamin D deficiency and
matched controls for further validation; future studies are needed to replicate and validate
the findings by independent methods in independent cohorts including female populations.
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Legend: Volcano plot showing raw p-values versus mean methylation differences between
severe vitamin D deficient cases and matched controls.
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Table 1
General characteristics of the African American male participants
Cases 25(OH)D ≤ 25 nmol/L & BMI < 85th
percentile
Controls 25(OH)D > 75 nmol/L & BMI < 85th
percentile
p
N 11 11 -
Age, years 16.2 ± 1.2 16.1 ± 1.3 0.791
Age range, years 14.8-18 14.2-18.6 -
Height, cm 174.6 ± 6.1 174.3 ± 8.8 0.930
Weight, kg 63.2 ± 7.4 62.5 ± 8.5 0.841
BMI, kg/m2 20.7 ± 2.5 20.6 ± 2.4 0.897
BMI percentile (%)* 43.6 ± 24.5 46.2 ± 25.8 0.739
Waist circumference, c m 71.2 ± 4.7 70.9 ± 4.3 0.878
SBP, mmHg 113.0 ± 5.7 112.6 ± 4.7 0.855
DBP, mmHg* 58.5 ± 6.1 58.2 ± 4.5 0.940
25(OH)D, nmol/L 19.8 ± 3.8 92.0 ± 12.4 <0.0001
Values are mean ± SD. Tests of significance between groups were based on independent t test. SBP: systolic blood pressure. DBP: diastolic blood
pressure.
*
BMI% and DBP were log-transformed prior to the analysis.
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Table III
Gene-Ontology analysis
GO. ID Term P value FDR
Biological process GO:0006139 Nucleotide and nucleic acid metabolic process 0.0081 0.936
GO:0019222 Regulation of metabolic process 0.014 0.936
GO:0050794 Regulation of cellular process 0.0141 0.936
GO:0048518 Positive regulation of biological process 0.0182 0.936
GO:0040029 Regulation of gene expression, epigenetic 0.0221 0.936
GO:0040012 Regulation of locomotion 0.0328 0.936
GO:0006928 Cell motility 0.036 0.936
GO:0030154 Cell differentiation 0.036 0.936
GO:0006968 Cellular defense response 0.0409 0.936
GO:0050790 Regulation of catalytic activity 0.0469 0.936
GO:0043283 Biopolymer metabolic process 0.0481 0.936
Molecular function GO:0008134 Transcriptional factor binding 0.00058 0.11
GO:0032934 Sterol binding 0.00079 0.11
GO:0030020 Extracellular matrix structural constituent conferring tensile strength 0.0063 0.58
GO:0030023 Extracellular matrix constituent conferring elasticity 0.0125 0.78
GO:0003704 Specific RNA polymerase II transcription factor activity 0.0141 0.78
GO:0017147 Wnt-protein binding 0.0187 0.87
GO:0015248 Sterol transporter activity 0.0431 1
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